Reviva Pharmaceuticals Holdings, Inc. Stock-Based Compensation
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Stock-Based Compensation of $799.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $214.56K, a 45.72% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $584.44K, a 36.41% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $455.08K, a 17.89% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $458.38K, a 31.70% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.23M, a 36.65% increase from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.63M, a 52.24% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.41M, a 1831.34% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $176.74K, a 65.62% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $214.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $799.00K 10-Q · filed 2026-08-12 | $1.25M derived: sum of 3 quarters · filed 2026-08-12 | $1.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $584.44K 10-Q · filed 2026-05-13 | $1.04M derived: sum of 2 quarters · filed 2026-05-13 | $1.50M derived: sum of 3 quarters · filed 2026-05-13 | $1.89M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $455.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $913.46K derived: sum of 2 quarters · filed 2026-03-30 | $1.31M derived: sum of 3 quarters · filed 2026-08-12 | $2.23M 10-K · filed 2026-03-30 |
| 2025-09-30 | $458.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $853.66K derived: sum of 2 quarters · filed 2026-08-12 | $1.77M 10-Q · filed 2025-11-13 | $2.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $395.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.31M 10-Q · filed 2026-08-12 | $1.87M derived: sum of 3 quarters · filed 2026-08-12 | $2.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $919.12K 10-Q · filed 2026-05-13 | $1.47M derived: sum of 2 quarters · filed 2026-05-13 | $1.82M derived: sum of 3 quarters · filed 2026-05-13 | $2.18M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $554.22K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $902.27K derived: sum of 2 quarters · filed 2026-03-30 | $1.26M derived: sum of 3 quarters · filed 2026-03-30 | $1.63M 10-K · filed 2026-03-30 |
| 2024-09-30 | $348.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $707.05K derived: sum of 2 quarters · filed 2025-11-13 | $1.08M 10-Q · filed 2025-11-13 | $1.47M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $358.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $728.07K 10-Q · filed 2025-08-14 | $1.12M derived: sum of 3 quarters · filed 2025-08-14 | $1.47M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $369.07K 10-Q · filed 2025-05-15 | $759.67K derived: sum of 2 quarters · filed 2025-05-15 | $1.11M derived: sum of 3 quarters · filed 2025-05-15 | $3.73M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $390.60K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $741.01K derived: sum of 2 quarters · filed 2025-04-03 | $3.36M derived: sum of 3 quarters · filed 2025-04-03 | $3.41M 10-K · filed 2025-04-03 |
| 2023-09-30 | $350.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.97M derived: sum of 2 quarters · filed 2024-11-14 | $3.02M 10-Q · filed 2024-11-14 | $3.08M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.67M 10-Q · filed 2024-08-14 | $2.73M derived: sum of 3 quarters · filed 2024-08-14 | $2.77M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $51.53K 10-Q · filed 2024-05-14 | $108.11K derived: sum of 2 quarters · filed 2024-05-14 | $148.70K derived: sum of 3 quarters · filed 2024-05-14 | $188.58K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $56.59K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $97.17K derived: sum of 2 quarters · filed 2024-04-15 | $137.05K derived: sum of 3 quarters · filed 2024-04-15 | $176.74K 10-K · filed 2024-04-15 |
| 2022-09-30 | $40.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $80.46K derived: sum of 2 quarters · filed 2023-11-14 | $120.15K 10-Q · filed 2023-11-14 | $182.18K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $39.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $79.56K 10-Q · filed 2023-08-14 | $141.60K derived: sum of 3 quarters · filed 2023-08-14 | $169.19K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $39.69K 10-Q · filed 2023-05-15 | $101.72K derived: sum of 2 quarters · filed 2023-05-15 | $129.31K derived: sum of 3 quarters · filed 2023-05-15 | $146.40K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $62.03K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $89.62K derived: sum of 2 quarters · filed 2023-03-30 | $106.71K derived: sum of 3 quarters · filed 2023-03-30 | $106.71K 10-K · filed 2023-03-30 |
| 2021-09-30 | $27.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $44.68K derived: sum of 2 quarters · filed 2022-11-14 | $44.68K 10-Q · filed 2022-11-14 | $44.68K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $17.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $17.09K 10-Q · filed 2022-08-15 | $17.09K derived: sum of 3 quarters · filed 2022-08-15 | $17.09K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $0.00 derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |